Yüklüyor......
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics
Dolutegravir (DTG) is a potent integrase inhibitor of human immunodeficiency virus. Because DTG is a substrate of the efflux transporter ABCG2 and ABCG2 is highly polymorphic, we asked whether dose adjustment of DTG is needed for ABCG2-deficient individuals. Using Abcg2-null mice, the current work i...
Kaydedildi:
| Yayımlandı: | J Pharmacol Exp Ther |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The American Society for Pharmacology and Experimental Therapeutics
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292963/ https://ncbi.nlm.nih.gov/pubmed/32303561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.264424 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|